Search
Search Results
##search.searchResults.foundPlural##
-
Improving BNT162b2 mRNA vaccine tolerability without efficacy loss by Pidotimod supplementation Pidotimod in SARS-CoV-2 vaccination
1054PDF: 527HTML: 208 -
The Outcome of Six Patients with COVID-19 Infection and Multiple Myeloma. A Case Series and Literature Review COVID-19 in Multiple Myeloma patients
919PDF: 338HTML: 173 -
CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS. Anti-CMV immunoglobulins for CMV treatment
1880PDF: 1137HTML: 256 -
TYROSINE KINASE INHIBITORS AND INTERFERON
2810PDF: 1398HTML: 3040Cover Letter: 187 -
ROLE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION
1978PDF: 773HTML: 1027 -
Invasive Pulmonary Aspergillosis in a Sickle Cell Patient Transplant Recipient: A Successful Treatment
1876PDF: 1071HTML: 1886Lung computed tomography CT scan image: 187 -
AUTOIMMUNE CYTOPENIAS IN CHRONIC LYMPHOCYTIC LEUKEMIA, FACTS AND MYTHS
2133PDF: 1168HTML: 3691 -
CAN WE PREDICT INCIPIENT DIABETES MELLITUS IN PATIENTS WITH TRANSFUSION DEPENDENT β-THALASSEMIA (β-TDT) REFERRED WITH A HISTORY OF PREDIABETES? Risk factors for incipient diabetes in thalassemia
1005PDF: 1310HTML: 92 -
EVALUATION OF USING EMPIRIC GLYCOPEPTIDES IN ACCORDANCE WITH THE IDSA GUIDELINE IN HEMATOLOGIC MALIGNANCY PATIENTS WITH FEBRILE NEUTROPENIA Empiric glycopeptide use in neutropenic fever
1391PDF: 1023HTML: 207 -
THE EVOLVING ROLE OF RADIOTHERAPY IN EARLY STAGE HODGKIN’S LYMPHOMA
2171PDF: 923HTML: 6769Figure 1: 158 -
Cardiac toxicity associated with HCV direct antiviral agents Heart in HCV DAAs therapy
1517PDF: 950HTML: 163 -
Evaluating the use of meropenem in hematologic patients with febrile neutropenia A retrospective observational single-cohort study
906PDF: 409HTML: 115 -
THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION
4001PDF: 1888HTML: 1749 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2185PDF: 1013HTML: 1973Characteristic of study group: 181 -
LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
1560PDF: 776HTML: 841jdoe, table 2 infections CML .doc: 177jdoe, table 1 infections CML .doc: 165 -
DIAGNOSTIC ACCURACY OF CLINICAL TOOL ‘STOPS’ AND SERUM PROCALCITONIN FOR OPTIMIZING ANTIBIOTIC THERAPY IN NEONATAL SEPSIS STOPS and procalcitonin for optimizing antibiotics in neonatal sepsis
1521PDF: 551HTML: 358 -
Massive pulmonary embolism at the onset of acute promyelocytic leukemia
3440PDF: 857HTML: 1634figure 1: 151Untitled: 176 -
Focusing On A Unique Innate Memory Cell Population Of Natural Killer Cells In The Fight Against COVID-19: Harnessing The Ubiquity Of Cytomegalovirus Exposure Memory Cell Population Of Natural Killer Cells in COVID-19 and Cytomegalovirus Exposure
1103PDF: 885HTML: 281 -
DIAGNOSIS OF MALARIA INFECTION WITH OR WITHOUT DISEASE
3542PDF: 1089HTML: 23319 -
THE Co-Occurrence of Jak2/Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib. Dual Myeloid Disorder Treated with Two Drug Association
988PDF: 985HTML: 88 -
CROCIN PROMOTES APOPTOSIS IN HUMAN EBV-TRANSFORMED B-LYMPHOCYTE VIA INTRINSIC PATHWAY CROCIN PROMOTES APOPTOSIS IN EBV-TRANSFORMED LCL
1194PDF: 453HTML: 129







